- Bradford
A. Young, Ph.D., MBA was recently appointed senior vice president and
chief commercial officer
- A very
accomplished and experienced businessman and scientist, Young has helped
guide and grow both startups and large companies
- Young
is expected to leverage his technical expertise and real-world experience
to drive revenue growth via major partnerships and new commercialization
programs
A leader in the development and commercialization of
innovative, pressure-based technologies for the worldwide life sciences
industry, Pressure BioSciences Inc. (OTCQB: PBIO) recently appointed Dr.
Bradford A. Young as its senior vice president and chief commercial officer.
The move is designed to help drive the company’s revenue growth and expand its
commercialization programs by leveraging Young’s experience as both a scientist
and a well-connected and experienced businessman.
Speaking about the appointment during a recent Uptick
Newswire Stock Day Podcast with Everett Jolly (http://ibn.fm/Yw0lD), Pressure
BioSciences CEO Richard T. Schumacher praised Young for his many
accomplishments, as well as his academic and entrepreneurial background. Young
has a Ph.D. in biochemistry from the University of Maryland School of Medicine
and an MBA from the University of California, Berkeley, Haas School of
Business.
“He is quite a fellow. I’ve known him personally and
professionally for over six years. (…) He combines the acumen, skills and
experience of someone who has had both entrepreneurial as well as big company
experience,” the Pressure BioSciences CEO noted in the interview.
Young joins the Pressure BioSciences management team with a
solid entrepreneurial background and the experience of providing executive
level consulting for strategic planning, product development and
commercialization to various biomedical, diagnostic and pharmaceutical
companies. In his new position as senior vice president and chief commercial
officer, he will play a critical role in advancing the company’s
commercialization programs and overall strategic planning, with a view toward
establishing new and/or enhanced revenue opportunities and significant
partnerships.
More specifically, Young will promote the company’s
instruments, consumables and technology platforms with synergistic companies
worldwide, with a goal of integrating Pressure BioSciences’ products into their
offerings. These types of collaborations and partnerships could result in major
volume sales, enabling the company to significantly boost its revenue.
“Dr. Young will be designing and implementing PBI’s
commercial programs, including business development. He will be working with
many companies that we believe should be and could be offering our sample
preparation systems together with their own analytical instrumentation,”
Schumacher said during the Stock Day Podcast. “We think this type of
collaboration will let one plus one equal three. Our instruments are used to
break apart samples to prepare them to be tested, while the companies he will
be speaking with offer the analytical equipment that is used to test the
samples. It makes total sense to put our sample preparation systems together
with their analytical instruments.”
In addition to accelerating revenue growth via critical
partnerships and new commercialization programs, Young will also assess multiple
opportunities for expansion into new and divergent markets, optimize
commercialization priorities and work to advance customer adoption.
Before joining Pressure BioSciences, Young held a number of
management positions with both large and small companies, including founder and
CEO of AddisonField Corporation, a biotech company developing consumer health
products; vice president of business development for Nodality, a pharmaceutical
services provider offering disease and drug profiling in autoimmune diseases
and oncology; director of market and business development for Quest Diagnostics
(NYSE: DGX), one of the largest clinical reference laboratories in the U.S.;
and head of market development with Celera, a personalized medicine pioneer. He
also serves on the board of directors of circulating tumor cell diagnostics
company Liquid Biotech, Inc., and is a selection committee member for the
Stanford Predictive and Diagnostics Accelerator program.
In a recent news release announcing his appointment (http://ibn.fm/tuajI), Young
voiced excitement in joining the Pressure BioSciences team at a time when he
can help develop and lead commercial strategies designed to promote the
company’s patented, pressure-based technology platforms while working to
enhance adoption rates and sales.
“I look forward to leading the company’s commercialization
and strategic partnership efforts in its highly-respected core area of pressure
cycling technology (PCT) products, as well as its recently acquired PreEMT
platform for improving the development of protein therapeutics. I am
particularly excited to become part of PBI’s team that is developing the
Company’s powerful new Ultra Shear Technology (”UST”) platform. I believe that
UST can open up a vast range of market opportunities for nano-scale emulsions,
including in the nutraceuticals (e.g., CBD oil), cosmetics, pharmaceuticals,
and food industries,” he said.
For more information, visit the company’s website at www.PressureBioSciences.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment